Encoded Therapeutics, which was incubated in Illumina’s accelerator, has captured $104m in a series C round backed by the corporate’s strategic investment unit, Illumina Ventures.
US-based precision gene therapy developer Encoded Therapeutics raised $104m on Wednesday in a series C round that included Illumina Ventures, the corporate venturing subsidiary of biotechnology developer Illumina.
Alexandria Venture Investments, the venture capital unit for life sciences real estate investment trust Alexandria Real Estate Equities, also took part in the round, as did Venrock, Arch Venture Partners, Matrix Capital Management, Altitude Life Science Ventures, Menlo Ventures, RTW Investments and Boxer Capital.
Founded in 2014, Encoded Therapeutics exploits genomics and…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
